Advancements and challenges in CAR-NK cell therapy for cancer treatment
Trends in Biotechnology · 2026-09 · 44 (9) · 2511-2529
DOI: 10.1016/j.tibtech.2025.12.020 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Biotechnology, 2026-09. Verfasst von Zhengshui Xu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, China; Ministry of Education, Key…. Hauptthemen laut MEDLINE: Neoplasms, Killer Cells, Natural, Receptors, Chimeric Antigen, Immunotherapy, Adoptive. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 99 Literaturangaben. Gefördert von: Yulin Science and Technology Bureau, National Natural Science Foundation of China, Natural Science Basic Research Program of Shaanxi Province.
Abstract (Originalsprache)
Chimeric antigen receptor natural killer (CAR-NK) cell therapy is an emerging cancer treatment offering advantages over CAR-T therapy, including reduced risks of cytokine release syndrome and graft-versus-host disease. This review highlights how genetic engineering enhances natural killer cells' innate tumor-killing abilities through CAR expression. Preclinical and clinical studies show promising antitumor responses, yet challenges remain, such as ensuring in vivo persistence, overcoming the immunosuppressive tumor microenvironment, and addressing manufacturing hurdles. Strategies such as cytokine support, combination therapies, and novel CAR designs are explored to improve efficacy. Future directions include personalized approaches, novel antigen targets, and artificial intelligence integration. CAR-NK therapy holds strong potential as a safe, scalable, and effective modality in cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, China; Ministry of Education, Key Laboratory of Surgery Critical Care and Life Support (Xi'an Jiaotong…
- Department of Thoracic Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, China.
- The Second Department of Oncology, Huizhou First Hospital, Huizhou, Guangdong, China.
- Department of General Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China.
- Department of Oncology, Liuzhou People's Hospital, Guangxi Medical University, No. 8, Wenchang Road, Chengzhong District, Liuzhou, Guangxi 545006, China.
- Medical Innovation Research Department, Chinese PLA General Hospital, Beijing 100853, China.
Förderung
- Yulin Science and Technology Bureau
- National Natural Science Foundation of China
- Natural Science Basic Research Program of Shaanxi Province
- Institute for Health Metrics and Evaluation
- University of Washington
- Fundação para a Ciência e a Tecnologia
Zitieren
APA
Xu, Z., Li, Y., Zhou, Y., Ye, C., Kuang, J., Yin, C., Zhao, D., Guo, H., Chellamani, N., Shanmuganathan, M., Conde, J., & Liu, S. (2026). Advancements and challenges in CAR-NK cell therapy for cancer treatment. Trends in Biotechnology, 44(9), 2511-2529. https://doi.org/10.1016/j.tibtech.2025.12.020
Vancouver
Xu Z, Li Y, Zhou Y, Ye C, Kuang J, Yin C, et al. Advancements and challenges in CAR-NK cell therapy for cancer treatment. Trends in Biotechnology. 2026;44(9):2511-2529. doi:10.1016/j.tibtech.2025.12.020
BibTeX
@article{Xu2026,
author = {Xu, Zhengshui and Li, Yu and Zhou, Yundong and Ye, Changchun and Kuang, Junjie and Yin, Chengliang and Zhao, Danwen and Guo, Hui and Chellamani, Narmatha and Shanmuganathan, Manimurugan and Conde, João and Liu, Shiyuan},
title = {Advancements and challenges in CAR-NK cell therapy for cancer treatment},
journal = {Trends in Biotechnology},
year = {2026},
volume = {44},
number = {9},
pages = {2511--2529},
doi = {10.1016/j.tibtech.2025.12.020}
}
EUVIMED